- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Amgen Appeal Will Delay Marketing of Novartis Biosimilar
The appeals court decision has ensured that Novartis cannot bring its biosimilar Zarxio (filgrastim), which provides immune support to cancer patients, to the market at least till June 3.
A US appeals court has blocked Novartis AG from selling its knockoff version of an Amgen Inc. cancer supportive-care drug in the US until the court resolves a legal fight between the rivals.
The US Court of Appeals for the Federal Circuit in Washington on May 5 granted Amgen's request for an injunction blocking Novartis' Zarxio from the US market until the court resolves Amgen's appeal of a lower-court ruling that gave the green light to Zarxio's market entry.
The new order is expected to keep Zarxio off the US market at least until June 3, when oral arguments are scheduled, though resolution of the case could take longer.
Complete news on Nasdaq: http://bit.ly/1QsTGKK
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More
